Stifel resumed coverage on Cullinan Therapeutics with a new price target
$CGEM
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Stifel resumed coverage of Cullinan Therapeutics with a rating of Buy and set a new price target of $22.00